Lifeboat Foundation

The compound inside the mushroom could be used to treat Alzheimer’s.

An active compound found in an edible mushroom may just be able to improve nerve growth and enhance memory leading to treatments for debilitating diseases such as Alzheimer’s.

The mushroom can be found in North America, Europe, and Asia. In traditional Chinese medicine, it is used to boost the immune system and improve digestive health.

Continue reading “Active compound in an edible mushroom is found to boost memory” »

Some problems need a lifetime of thinking.

Nick Axten was recently awarded his doctoral degree by the University of Bristol in the U.K. While doctoral students usually take five or six years to complete their program, it took Nick 52 years to go from Mr. Axten to Dr. Axten.

Problems that take a lifetime.

Continue reading “British man awarded doctorate 52 years after starting his Ph.D” »

The Methuselah Foundation is a non-profit medical charity focused on extending the healthy human lifespan by making 90 the new 50 by 2030. Our goal is to accelerate results in the longevity field, as well as the biotechnology, regenerative medicine, life sciences sectors. We incubate and sponsor mission-relevant ventures, fund research, and support projects and prizes.

When people talk about the problems of aging, they most often focus on aches and pains, chronic conditions like heart failure or diabetes, and neurological disorders like Parkinson’s or Alzheimer’s. Often overlooked is the extremely common problem of loneliness.

The Methuselah Foundation is a non-profit medical charity focused on extending the healthy human lifespan by making 90 the new 50 by 2030. Our goal is to accelerate results in the longevity field, as well as the biotechnology, regenerative medicine, life sciences sectors. We incubate and sponsor mission-relevant ventures, fund research, and support projects and prizes.

Yes, it’s possible. Using genomic technologies and specialized mouse models to develop preventative therapies, JAX scientists aim to stop Alzheimer’s before it starts.

University of Chicago scientists have discovered a new wrinkle in our understanding of how our genes work. The team, led by Chuan He, the UChicago John T. Wilson Distinguished Service Professor of Chemistry, Biochemistry and Molecular Biology, shed light on a longstanding puzzle involved in a common way our genes are modified that is known as RNA methylation.

Published Jan. 27 in Science, the finding could have implications for gene therapies for disease, as well as our picture of gene expression, development, and evolution.

For more than a decade, Chuan He’s laboratory has been focused on trying to unravel the puzzle of a phenomenon called RNA methylation, which we are increasingly understanding plays a key role in our bodies and lives—everything from cancer to PTSD to aging.

The behavioral disorders observed in autism are associated with a multitude of genetic alterations. Scientists from the Hector Institute for Translational Brain Research (HITBR) have now found another molecular cause for this condition. The transcription factor MYT1L normally protects the molecular identity of nerve cells. If it is genetically switched off in human nerve cells or in mice, the functional changes and symptoms typical of autism occur. A drug that blocks sodium channels in the cell membrane can reverse the consequences of MYT1L failure and alleviate the functional and behavioral abnormalities in mice.

Disorders from the autism spectrum (ASD, autism spectrum disorders) are not only manifested by impairments in social interaction, communication, interest formation, and by stereotypical behavior patterns. This is often accompanied by other abnormalities such as epilepsy or hyperactivity.

Scientists are intensively searching for the molecular abnormalities that contribute to this complex developmental disorder. A multitude of genetic factors that influence the molecular programs of the nerve cells have already been linked to the development of autism.

The World Health Organization hopes to test an experimental Marburg vaccine in Equatorial Guinea, which announced its first outbreak of the virus Monday.

Nine deaths have been confirmed, while 16 suspected patients are in quarantine. Health officials are also monitoring 15 asymptomatic close contacts of infected people.

No vaccine or antiviral treatment is approved to treat Marburg virus disease, which has an average death rate of around 50%, according to the WHO.